Kaloianova A, Nikolov G, Tsolov S, Sotirov I, Tsanov N
Vutr Boles. 1986;25(4):54-60.
The authors follow up the effectiveness and tolerance of monotherapy with acebutolol in 47 patients with light and moderate hypertension, in a dose of 400-1200 mg in the course of three months. Twenty two of the patients have been treatment with the original French drug of the firm "Specia" and the rest 25--with the Bulgarian preparation, produced by Pharmachim according to a licence of the French one. The following parameters were followed up: arterial pressure, pulse rate, ECG, eventual adverse effects on 30, 60, 90 day of the treatment. The indices of cardiac output and total peripheral vascular resistance were calculated in a group of 13 patients. The results obtained reveal that the monotherapy with acebutolol, in light and moderate arterial hypertension, leads to definite, lasting and progressive antihypertensive effect in over 75% of the patients. The preparation has no significant effect on pulse rate and induces no orthostatism. It affected the total peripheral vascular resistance with 26% from the initial with unchanged or lightly increased indices of cardiac output. The Bulgarian drug, produced by Pharmachim, gives no way in effectiveness to the original French preparation.
作者对47例轻、中度高血压患者进行了为期三个月的醋丁洛尔单药治疗，剂量为400 - 1200毫克，观察其有效性和耐受性。其中22例患者使用法国“Specia”公司的原装药物治疗，其余25例使用保加利亚Pharmachim公司根据法国许可证生产的制剂治疗。观察了以下参数：治疗第30、60、90天的动脉血压、脉搏率、心电图以及可能出现的不良反应。对13例患者计算了心输出量和总外周血管阻力指数。结果显示，在轻、中度动脉高血压患者中，醋丁洛尔单药治疗使超过75%的患者产生明确、持久且逐渐增强的降压效果。该制剂对脉搏率无显著影响，也不引起体位性低血压。它使总外周血管阻力较初始值降低了26%，而心输出量指数不变或略有增加。Pharmachim公司生产的保加利亚药物在疗效上不逊色于法国原装制剂。
